meta
|
evidence
oncology
Living systematic review and meta-analysis
RET gene alteration defined cancer
2
glioblastoma (GB)
1
<span style="margin-left: 0em;">immune chekpoint inhibitors</span>
<span style="margin-left: 1em;">anti-PD-(L)1</span>
<span style="margin-left: 2em;">nivolumab based treatment</span>
<span style="margin-left: 3em;">nivolumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 2em;">pembrolizumab based treatment</span>
<span style="margin-left: 3em;">pembrolizumab plus SoC <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 0em;">VEGF(R) inhibitor</span>
<span style="margin-left: 1em;">bevacizumab based treatment</span>
<span style="margin-left: 2em;">bevacizumab <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (1)
progression or deaths (PFS) (1)
objective responses (ORR) (1)
DOR (1)
TRAE (any grade) (1)
TRAE (grade 3-4) (1)
TRAE leading to death (grade 5) (1)
Pruritus TRAE (grade 3-4) (1)
Rash TRAE (grade 3-4) (1)
Diarrhoea TRAE (grade 3-4) (1)
Increased ALT TRAE (grade 3-4) (1)
Fatigue TRAE (grade 3-4) (1)
Nausea TRAE (grade 3-4) (1)
Pneumonitis TRAE (grade 3-4) (1)
Headache TRAE (grade 3-4) (1)
Increased lipase level TRAE (grade 3-4) (1)
Hypertension TRAE (grade 3-4) (1)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
insufficient data
Evidence network for deaths (OS)
1
Checkmate 143, 2020
bevacizumab
nivolumab alone
pembrolizumab plus SoC
direct evidence
network meta-analysis
comet plot
result box
odds ratio
A
B
0.5
1.5
1.0
odds ratio for A vs. B
and half 95% CI
T
vs.
C
bevacizumab
nivolumab alone
pembrolizumab plus SoC
bevacizumab
---
NA
NA
nivolumab alone
NA
---
NA
pembrolizumab plus SoC
NA
NA
---
pathologies: 61,202,203 - treatments: 873
result logic
×
Study list
